Increased YAP1 expression is significantly associated with breast cancer progression, metastasis and poor survival
- PMID: 33880946
- DOI: 10.2217/fon-2020-1080
Increased YAP1 expression is significantly associated with breast cancer progression, metastasis and poor survival
Abstract
YAP1 plays a key role as a transcriptional coactivator in the Hippo pathway. Based on conflicting reports regarding YAP1 function in cancer, this study discerned its role in breast carcinogenesis. First, a systematic review of salient breast cancer studies targeting YAP1 dysregulation was performed. Additionally, freshly excised tumor specimens of approximately 200 breast cancer patients were processed for quantification of YAP1 expression at mRNA and protein levels using quantitative PCR and immunohistochemistry, respectively. YAP1 expression was nine folds higher in tumors versus controls and significantly associated with metastasis (p < 0.05) and poor survival in Pakistani breast cancer patients. These findings establish the role of YAP1 overexpression in tumorigenesis and metastasis. Hence, YAP1 inhibition may be considered a possible therapeutic strategy.
Keywords: YAP1; breast cancer; expression; metastasis; prognosis.
Plain language summary
Lay abstract Breast cancer incidence and prevalence are rapidly increasing across the globe, especially in countries with poor screening interventions, culminating in delayed diagnosis and greater mortality. Furthermore, for the adequate treatment of breast cancer, treatment plans must be individualized. In this context, the present study was devised to add to the existing pool of information with regard to breast cancer. In addition, the authors wanted to see whether YAP1 (the gene of interest) significantly contributes to breast cancer progression and its spread to distant areas of the body. Also, the authors aimed to study the effect of this gene on survival in breast cancer patients. Knowing the role of YAP1 in breast cancer, it is imperative to make use of this gene in devising treatment strategies for the proper management of breast cancer patients.
Similar articles
-
EIF3H Orchestrates Hippo Pathway-Mediated Oncogenesis via Catalytic Control of YAP Stability.Cancer Res. 2020 Jun 15;80(12):2550-2563. doi: 10.1158/0008-5472.CAN-19-3718. Epub 2020 Apr 8. Cancer Res. 2020. PMID: 32269044 Free PMC article.
-
Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal.Cancer Rep (Hoboken). 2022 Mar;5(3):e1484. doi: 10.1002/cnr2.1484. Epub 2021 Jun 30. Cancer Rep (Hoboken). 2022. PMID: 34196131 Free PMC article.
-
USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer.Oncogene. 2022 Apr;41(18):2555-2570. doi: 10.1038/s41388-022-02267-0. Epub 2022 Mar 22. Oncogene. 2022. PMID: 35318441
-
ARID1A-mutated cervical cancer depends on the activation of YAP signaling.Front Biosci (Landmark Ed). 2021 Dec 30;26(12):1411-1421. doi: 10.52586/5035. Front Biosci (Landmark Ed). 2021. PMID: 34994156
-
Long noncoding RNA LINC00473 indicates a poor prognosis of breast cancer and accelerates tumor carcinogenesis by competing endogenous sponging miR-497.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3410-3420. doi: 10.26355/eurrev_201904_17705. Eur Rev Med Pharmacol Sci. 2019. PMID: 31081095
Cited by
-
α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1.Cancer Gene Ther. 2023 Dec;30(12):1624-1635. doi: 10.1038/s41417-023-00665-4. Epub 2023 Sep 7. Cancer Gene Ther. 2023. PMID: 37679528
-
ER-mitochondria tethering and its signaling: A novel therapeutic target in breast cancer.Mol Ther Oncol. 2025 May 14;33(2):200995. doi: 10.1016/j.omton.2025.200995. eCollection 2025 Jun 18. Mol Ther Oncol. 2025. PMID: 40496927 Free PMC article. Review.
-
USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells.Med Oncol. 2023 Dec 27;41(1):33. doi: 10.1007/s12032-023-02272-7. Med Oncol. 2023. PMID: 38150085
-
The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.Front Immunol. 2022 Nov 21;13:1012173. doi: 10.3389/fimmu.2022.1012173. eCollection 2022. Front Immunol. 2022. PMID: 36479120 Free PMC article.
-
YAP1 activates SLC2A1 transcription and augments the malignant behavior of colorectal cancer cells by activating the Wnt/β-catenin signaling pathway.Cell Div. 2025 Apr 4;20(1):8. doi: 10.1186/s13008-025-00148-y. Cell Div. 2025. PMID: 40186232 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical